Nuveen LLC Makes New $1.04 Million Investment in AnaptysBio, Inc. $ANAB

Nuveen LLC bought a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 56,012 shares of the biotechnology company's stock, valued at approximately $1,041,000. Nuveen LLC owned about 0.19% of AnaptysBio as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also modified their holdings of ANAB. Fairmount Funds Management LLC acquired a new position in shares of AnaptysBio in the 4th quarter valued at approximately $24,050,000. Sanofi acquired a new position in shares of AnaptysBio in the 4th quarter valued at approximately $10,882,000. Woodline Partners LP raised its holdings in AnaptysBio by 5.5% in the fourth quarter. Woodline Partners LP now owns 485,073 shares of the biotechnology company's stock valued at $6,422,000 after acquiring an additional 25,094 shares in the last quarter. Soleus Capital Management L.P. acquired a new stake in AnaptysBio in the fourth quarter valued at $5,481,000. Finally, Victory Capital Management Inc. raised its holdings in AnaptysBio by 21.5% in the first quarter. Victory Capital Management Inc. now owns 406,430 shares of the biotechnology company's stock valued at $7,556,000 after acquiring an additional 71,980 shares in the last quarter.

Insiders Place Their Bets

In other AnaptysBio news, Director Hollings Renton sold 20,925 shares of the stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $23.57, for a total value of $493,202.25. Following the sale, the director directly owned 4,965 shares of the company's stock, valued at $117,025.05. This trade represents a 80.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 33.50% of the stock is owned by corporate insiders.

AnaptysBio Trading Up 3.8%

AnaptysBio stock traded up $0.81 during mid-day trading on Friday, reaching $21.90. The company's stock had a trading volume of 402,655 shares, compared to its average volume of 446,507. The firm has a market cap of $613.20 million, a price-to-earnings ratio of -4.89 and a beta of -0.19. The business has a 50 day moving average price of $23.13 and a 200-day moving average price of $20.92. AnaptysBio, Inc. has a twelve month low of $12.21 and a twelve month high of $40.70.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported ($1.34) EPS for the quarter, topping analysts' consensus estimates of ($1.50) by $0.16. The firm had revenue of $22.26 million during the quarter, compared to the consensus estimate of $11.55 million. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%. On average, equities analysts expect that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on ANAB. Guggenheim reaffirmed a "buy" rating and issued a $90.00 price target (up from $54.00) on shares of AnaptysBio in a report on Wednesday, May 28th. UBS Group reaffirmed a "neutral" rating and issued a $20.00 price target (up from $18.00) on shares of AnaptysBio in a report on Tuesday, August 12th. Wedbush upped their price target on shares of AnaptysBio from $40.00 to $45.00 and gave the company an "outperform" rating in a report on Thursday, August 7th. JPMorgan Chase & Co. upped their price target on shares of AnaptysBio from $42.00 to $80.00 and gave the company an "overweight" rating in a report on Thursday, July 24th. Finally, HC Wainwright raised shares of AnaptysBio from a "neutral" rating to a "buy" rating and upped their price target for the company from $22.00 to $38.00 in a report on Wednesday, June 4th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $46.13.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.